<div id="readability-page-1"><p>Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John Desjarlais sold 73,367 shares of Xencor stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares of the company's stock, valued at $3,718,943.28. This represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.</p><h2>Xencor Price Performance</h2><p>NASDAQ:XNCR opened at $15.22 on Friday. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $24.88. The stock's fifty day moving average price is $15.51 and its two-hundred day moving average price is $11.43. The company has a market cap of $1.09 billion, a P/E ratio of -8.60 and a beta of 0.96. </p><p>Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.64. The company had revenue of $21.00 million for the quarter, compared to analyst estimates of $29.73 million. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The firm's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.71) EPS.  On average, analysts expect that  Xencor, Inc. will post -3.68 earnings per share for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><p>XNCR has been the topic of several recent analyst reports. Barclays increased their target price on shares of Xencor from $23.00 to $26.00 and gave the stock an &#34;overweight&#34; rating in a research note on Wednesday, December 17th. Wedbush  reissued an &#34;outperform&#34; rating and set a $26.00 price objective on shares of Xencor in a research note on Thursday, November 6th. Bank of America cut Xencor from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and reduced their target price for the stock from $23.00 to $12.00 in a research report on Wednesday, September 3rd. Royal Bank Of Canada upped their target price on Xencor from $18.00 to $19.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald raised their price target on Xencor from $40.00 to $42.00 and gave the company an &#34;overweight&#34; rating in a report on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $24.88.</p><p><b>Get Our Latest Stock Report on Xencor</b></p><h2>Institutional Investors Weigh In On Xencor</h2><p>A number of large investors have recently added to or reduced their stakes in XNCR. Amalgamated Bank lifted its position in  Xencor by 4.8% in the 3rd quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company's stock worth $245,000 after buying an additional 947 shares during the last quarter.  HighVista Strategies LLC raised its stake in shares of  Xencor by 4.3% during the second quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $262,000 after acquiring an additional 1,362 shares in the last quarter.  GAMMA Investing LLC boosted its stake in shares of  Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 1,449 shares in the last quarter.  Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of  Xencor by 9.1% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company's stock valued at $144,000 after purchasing an additional 1,525 shares during the last quarter.  Finally, State of Tennessee Department of Treasury raised its position in  Xencor by 6.2% in the 2nd quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 1,784 shares during the period. </p><h2>About Xencor</h2> (Get Free Report)<p>Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.  </p><p>The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.</p><h2>See Also</h2><ul><li>Five stocks we like better than Xencor</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Xencor Right Now?</h2><p>Before you consider Xencor, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.</p><p>While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

XNCR

<p>Xencor VP John Desjarlais sold 73,367 shares at $15.72 each, totaling $1,153,329.24. Post-sale, he owns 236,574 shares, a 23.67% decrease. Xencor's stock opened at $15.22 on Friday. The company reported Q3 earnings of ($0.08) per share, beating estimates. Analysts have mixed ratings, with a consensus price target of $24.88. Institutional investors have adjusted their stakes in Xencor.</p>

Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares